Share on StockTwits

Shares of Gilead Sciences (NASDAQ:GILD) saw unusually large options trading activity on Tuesday. Traders purchased 23,938 put options on the stock, American Banking reports. This represents an increase of 116% compared to the average volume of 11,107 put options.

In other Gilead Sciences news, Director John Francis Cogan sold 5,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $101.09, for a total transaction of $505,450.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on GILD. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $105.55.

Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.10% on Tuesday, hitting $106.27. 18,761,724 shares of the company’s stock traded hands. Gilead Sciences has a one year low of $58.50 and a one year high of $107.53. The stock’s 50-day moving average is $92.9 and its 200-day moving average is $82.26. The company has a market cap of $160.6 billion and a price-to-earnings ratio of 24.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.00 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.